Oxford Biomedica Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Oxford Biomedica stock has a consensus rating of "Strong Buy" and an average price target of 842p. The average 1-year stock price forecast is 36.97% higher than the current stock price, while the lowest is 550p (-10.57%) and the highest is 1,140p (+85.37%).

Price Target: 842p (+36.97%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	550p	842p	827p	1,140p
Change	-10.57%	+36.97%	+34.39%	+85.37%

Analyst Ratings

The average analyst rating for Oxford Biomedica stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	4	6	6	6	6	6
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Charles Weston RBC Capital	RBC Capital	Buy Reiterates 1,170p → 1,140p	Buy	Reiterates	1,170p → 1,140p	+85.37%	Jun 24, 2026
James Vane Jefferies	Jefferies	Buy Reiterates 827p	Buy	Reiterates	827p	+34.47%	Jun 3, 2026
James Orsborne Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates 950p	Buy	Reiterates	950p	+54.47%	Mar 11, 2026
Kane Slutzkin Deutsche Bank	Deutsche Bank	Buy Upgrades 380p → 735p	Buy	Upgrades	380p → 735p	+19.51%	Jan 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

228.04M

from 168.74M

35.14%

from 168.74M

Revenue Next Year

288.21M

from 228.04M

26.39%

from 228.04M

EPS This Year

-0.11

from -0.27

EPS Next Year

0.13

from -0.11

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	142.80M	139.99M	89.54M	128.80M	168.74M	228.04M
Revenue Growth	62.77%	-1.97%	-36.04%	43.85%	31.01%	35.14%
Gross Profit	82.64M	69.18M	39.73M	53.02M	65.98M	99.08M
Gross Margin	57.87%	49.42%	44.37%	41.17%	39.10%	43.45%
Operating Income	22.13M	-46.46M	-85.91M	-40.83M	-31.10M	-3.48M
Net Income	19.01M	-39.16M	-157.49M	-43.19M	-30.13M	-11.63M
EPS	-	-	-	-	-0.27	-0.11
Free Cash Flow	10.88M	-12.82M	-17.07M	-36.34M	-13.25K	-21.40M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.

Revenue Forecast

Revenue	2026	2027	2028
High	234.9M
Avg	228.0M
Low	222.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	39.2%
Avg	35.1%
Low	31.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.01
Avg	-0.11
Low	-0.18

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-